- Home
- FEBO vs BLRX Comparison
FEBO vs BLRX Comparison
Compare FEBO & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- BLRX
- Stock Information
- Founded
- FEBO 1993
- BLRX 2003
- Country
- FEBO Hong Kong
- BLRX Israel
- Employees
- FEBO N/A
- BLRX N/A
- Industry
- FEBO
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- FEBO
- BLRX Health Care
- Exchange
- FEBO Nasdaq
- BLRX Nasdaq
- Market Cap
- FEBO 12.7M
- BLRX 10.3M
- IPO Year
- FEBO 2023
- BLRX 2011
- Fundamental
- Price
- FEBO $1.22
- BLRX $3.00
- Analyst Decision
- FEBO
- BLRX Buy
- Analyst Count
- FEBO 0
- BLRX 2
- Target Price
- FEBO N/A
- BLRX $26.00
- AVG Volume (30 Days)
- FEBO 11.8K
- BLRX 30.2K
- Earning Date
- FEBO 05-02-2025
- BLRX 05-27-2025
- Dividend Yield
- FEBO N/A
- BLRX N/A
- EPS Growth
- FEBO N/A
- BLRX N/A
- EPS
- FEBO N/A
- BLRX N/A
- Revenue
- FEBO $16,319,897.00
- BLRX $28,940,000.00
- Revenue This Year
- FEBO N/A
- BLRX N/A
- Revenue Next Year
- FEBO N/A
- BLRX N/A
- P/E Ratio
- FEBO N/A
- BLRX N/A
- Revenue Growth
- FEBO 9.01
- BLRX 502.92
- 52 Week Low
- FEBO $0.93
- BLRX $2.30
- 52 Week High
- FEBO $17.68
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- FEBO 52.81
- BLRX 50.42
- Support Level
- FEBO $1.04
- BLRX $2.30
- Resistance Level
- FEBO $1.22
- BLRX $3.09
- Average True Range (ATR)
- FEBO 0.12
- BLRX 0.23
- MACD
- FEBO 0.01
- BLRX 0.06
- Stochastic Oscillator
- FEBO 62.07
- BLRX 88.87
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.